+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Human Insulin"

From
From
From
From
From
From
From
Insulin Glargine- - Biosimilar Insight, 2022 - Product Thumbnail Image

Insulin Glargine- - Biosimilar Insight, 2022

  • Report
  • January 2022
  • 90 Pages
  • Global
From
From
From
From
From
Global Insulin Market 2023-2027 - Product Thumbnail Image

Global Insulin Market 2023-2027

  • Report
  • December 2022
  • 154 Pages
  • Global
From
Human Insulin Drugs Market in Brazil 2024-2028 - Product Thumbnail Image

Human Insulin Drugs Market in Brazil 2024-2028

  • Report
  • December 2023
  • 142 Pages
  • Brazil
From
From
Loading Indicator

The Human Insulin market is a segment of the Endocrine and Metabolic Disorders Drugs market. It is composed of drugs used to treat diabetes, a condition in which the body does not produce enough insulin or is unable to use the insulin it produces. Human Insulin is a synthetic form of insulin, which is produced in a laboratory and is identical to the insulin produced by the human body. It is used to treat both type 1 and type 2 diabetes. Human Insulin is available in a variety of forms, including short-acting, intermediate-acting, and long-acting. It is typically administered via injection or an insulin pump. Some companies in the Human Insulin market include Novo Nordisk, Sanofi, Eli Lilly, and Biocon. Show Less Read more